



## Alnylam to Webcast Presentations at Upcoming December Investor Conferences

November 26, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 26, 2019-- [Alnylam Pharmaceuticals, Inc.](#) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

- Evercore ISI 2<sup>nd</sup> Annual HealthCONx Conference on Wednesday, December 4, 2019 at 1:15 pm ET at the Four Seasons Hotel in Boston
- Piper Jaffray 31<sup>st</sup> Annual Healthcare Conference on Thursday, December 5, 2019 at 9:00 am ET at the Lotte New York Palace Hotel in New York City

A live audio webcast of each presentation will be available on the Investors section of the Company's website, [www.alnylam.com](http://www.alnylam.com). A replay will be available on the Alnylam website within 48 hours after each event.

### About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), approved in the U.S., EU, Canada, Japan, and Switzerland, and GIVLAARI™ (givosiran), approved in the U.S. Alnylam has a deep pipeline of investigational medicines, including five product candidates that are in late-stage development. Alnylam is executing on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 1,200 people worldwide and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit [www.alnylam.com](http://www.alnylam.com) and engage with us on Twitter at [@Alnylam](#) or on [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191126005140/en/>

Source: Alnylam Pharmaceuticals, Inc.

### Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom  
(Investors and Media)  
617-682-4340

Josh Brodsky  
(Investors)  
617-551-8276